EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms

Nicola Marconato iD, Orazio De Tommasi, Dino Paladin, Diego Boscarino iD, Giulia Spagnol iD, Carlo Saccardi iD, Tiziano Maggino iD, Roberto Tozzi iD, Marco Noventa, Matteo Marchetti iD

Cancers · 25.05.2025 · 17 (11) · 1771

DOI: 10.3390/cancers17111771 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.05.2025. Verfasst von Nicola Marconato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women and Children's Health, University of Padua, 35128 Padua, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) is a key biomarker associated with increased sensitivity to PARP inhibitors (PARPi) in advanced epithelial ovarian cancer. Accurate identification of HRD status is essential for selecting patients most likely to benefit from these therapies. Current diagnostic approaches combine sequencing to detect mutations in homologous recombination repair genes—particularly BRCA1 and BRCA2—with genome-wide analysis of structural genomic alterations indicative of HRD. This review briefly outlines the biological basis of HRD and its clinical significance and then focuses on currently available assays for HRD assessment. We compare their molecular strategies, including the use of targeted gene panels and genomic instability metrics such as loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. The review also highlights the strengths and limitations of each platform and discusses their role in guiding clinical decision-making. Challenges related to dynamic tumor evolution and the interpretation of HRD status in recurrent disease settings are also addressed.

Schlagwörter

Stichwörter der Autor:innen

advanced epithelial ovarian cancerhomologous recombination deficiencyhomologous recombination repairpoly-ADP-ribose polymerase inhibitorstest

Autor:innen und Institutionen

  • Department of Women and Children's Health, University of Padua, 35128 Padua, Italy.
  • Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35128 Padua, Italy.
  • AB ANALITICA S.r.l., Via Svizzera, 16, 35127 Padova, Italy.

ORCID-Profile: Nicola Marconato, Diego Boscarino, Giulia Spagnol, Carlo Saccardi, Tiziano Maggino, Roberto Tozzi, Matteo Marchetti

Zitieren

APA

Marconato, N., Tommasi, O., Paladin, D., Boscarino, D., Spagnol, G., Saccardi, C., Maggino, T., Tozzi, R., Noventa, M., & Marchetti, M. (2025). Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms. Cancers, 17(11), 1771. https://doi.org/10.3390/cancers17111771

Vancouver

Marconato N, Tommasi O, Paladin D, Boscarino D, Spagnol G, Saccardi C, et al. Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms. Cancers. 2025;17(11):1771. doi:10.3390/cancers17111771

BibTeX
@article{Marconato2025,
  author = {Marconato, Nicola and Tommasi, Orazio De and Paladin, Dino and Boscarino, Diego and Spagnol, Giulia and Saccardi, Carlo and Maggino, Tiziano and Tozzi, Roberto and Noventa, Marco and Marchetti, Matteo},
  title = {Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {11},
  pages = {1771},
  doi = {10.3390/cancers17111771}
}
Kostenlos starten →